Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Wave crashes on DMD data as investors await Huntington’s readout

Wave drops DMD programs as data raise concerns about its stereopure oligonucleotides

Wave’s decision to discontinue its two Duchenne muscular dystrophy programs raised broader investor concerns about the company’s stereopure oligonucleotide platform and sent shares down more than 50% on Monday. Another readout for the platform in a second indication before year-end should provide more clues about the platform’s potential.

Wave Life Sciences Ltd. (NASDAQ:WVE) fell $20.81 (55%) to $16.79 on

Read the full 580 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers